Penumbra (PEN) EBT Margin Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -305.00 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -9.00 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -222.00 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 923.00 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -480.00 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 2,114.00 |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 1,391.00 |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -176.00 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 329.00 |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn | 754.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 754.00 |
| Dec 31, 2025 | 1,329.00 |
| Sep 30, 2025 | 1,333.00 |
| Jun 30, 2025 | 1,391.00 |
| Mar 31, 2025 | 1,603.00 |
| Dec 31, 2024 | 3,413.00 |
| Sep 30, 2024 | 912.00 |
| Jun 30, 2024 | -3,155.00 |
| Mar 31, 2024 | -212.00 |
| Dec 31, 2023 | 1,371.00 |
| Sep 30, 2023 | 1,797.00 |
| Jun 30, 2023 | 2,367.00 |
| Mar 31, 2023 | 413.00 |
| Dec 31, 2022 | -487.00 |
| Sep 30, 2022 | -787.00 |
| Jun 30, 2022 | -1,063.00 |
| Mar 31, 2022 | -1,178.00 |
| Dec 31, 2021 | -2,616.00 |
| Sep 30, 2021 | 2,190.00 |
| Jun 30, 2021 | -328.00 |
| Mar 31, 2021 | 298.00 |
| Dec 31, 2020 | -437.00 |
| Sep 30, 2020 | -1,454.00 |
| Jun 30, 2020 | -1,506.00 |
| Mar 31, 2020 | 185.00 |
| Dec 31, 2019 | 1,016.00 |
| Sep 30, 2019 | 1,092.00 |
| Jun 30, 2019 | 1,066.00 |
| Mar 31, 2019 | 561.00 |
| Dec 31, 2018 | 264.00 |
| Sep 30, 2018 | -2,194.00 |
| Jun 30, 2018 | 1,869.00 |
| Mar 31, 2018 | -650.00 |
| Dec 31, 2017 | 289.00 |
| Sep 30, 2017 | 25.00 |
| Jun 30, 2017 | -281.00 |
| Mar 31, 2017 | -926.00 |